Company intelligence / Profile preview
Ensol Biosciences Inc.
Daejeon, South Koreaensolbio.co.kr ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Lead drug Peniel 2000 is in Phase 3 for degenerative disc disease; Engedi 1000 in Phase 2 for osteoarthritis; Charis 1000 in Phase 1 for triple negative breast cancer; several other candidates in preclinical stages
- Therapeutic areas
- OncologyEndocrinologyDermatologyRheumatologyNeurologyInfectious Diseases
- Modalities
- Synthetic peptidesBio drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Yuhan Corp. (license-out agreement for joint development of osteoarthritis drug and degenerative disc disease)
Beyond the preview
Go deeper on Ensol Biosciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ensol Biosciences Inc..